Insys Therapeutics: Performance and Estimates for Q3

Insys Therapeutics

Insys Therapeutics (INSY) is a specialty pharmaceuticals company focused on developing cannabinoids and sprays. It reported EPS of -$0.37 on revenues of $23.47 million in the second quarter of 2018.

Insys Therapeutics: Performance and Estimates for Q3

The above chart compares Insys Therapeutics’ revenues since the first quarter of 2018 and estimates for the third quarter.

Quarterly revenue performance

Insys Therapeutics reported revenues of ~$23.47 million for the second quarter compared to ~$42.58 million for the second quarter of 2017.

Insys Therapeutics reports revenues for two product lines: Subsys and Syndros. Revenues for Subsys decreased to ~$22.47 million in the second quarter compared to ~$42.58 million in the second quarter of 2017. Revenues for Syndros were $0.99 million for the second quarter of 2018.

Estimate for Q3 2018

Wall Street analysts estimate that Insys Therapeutics could report revenues of $24.06 million in the third quarter of 2018. That’s a 21.6% decline compared to $30.67 million in the third quarter of 2017.

Performance in the first half of 2018

Insys Therapeutics reported revenues of $47.38 million for the first half of 2018. That compares to $78.54 million for the first half of 2017.

Revenues for Subsys decreased to ~$45.74 million in the first half of 2018 compared to ~$78.54 million in the first half of 2017. Revenues for Syndros were $1.63 million in the first half of 2018.

The iShares Nasdaq Biotechnology ETF (IBB) has 0.1% of its total investments in Insys Therapeutics (INSY), 0.1% in Cara Therapeutics (CARA), 0.8% in Sage Therapeutics (SAGE), and 0.1% in Corbus Pharmaceuticals Holdings (CRBP).